BGC Reports First Quarter 2026 Financial Results

BGC Reports First Quarter 2026 Financial Results

BGC Declares Quarterly Dividend of 2 Cents

Conference Call to Discuss Results Scheduled for 10:00 AM ET Today

NEW YORK–(BUSINESS WIRE)–
BGC Group, Inc. (Nasdaq: BGC) today reported its financial results for the first quarter ended March 31, 2026.

A complete financial results press release, including information about today’s conference call and BGC’s most recent dividend declaration, is available at http://ir.bgcg.com/, along with BGC’s earnings presentation and supplemental financial tables.

About BGC Group, Inc.

BGC Group, Inc. (Nasdaq: BGC) is a leading global marketplace, data, and financial technology services company for a broad range of products, including fixed income, foreign exchange, energy, commodities, shipping, equities, and now includes the FMX Futures Exchange. BGC’s clients are many of the world’s largest banks, broker-dealers, investment banks, trading firms, hedge funds, governments, corporations, and investment firms.

BGC and leading global investment banks and market making firms have partnered to create FMX, part of the BGC Group of companies, which includes a U.S. interest rate futures exchange, spot foreign exchange platform and the world’s fastest growing U.S. cash treasuries platform.

For more information about BGC, please visit www.bgcg.com.

Discussion of Forward-Looking Statements about BGC

Statements in this document regarding BGC that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, BGC undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see BGC’s Securities and Exchange Commission (“SEC”) filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

Investor Contact:

Jason Chryssicas

+1 212-610-2426

Media Contact:

Danielle Popper

+1 212-610-2419

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Data Analytics Finance Banking Data Management Professional Services Technology Fintech

MEDIA:

Logo
Logo

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam to Webcast Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

  • BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada

  • Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida.

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. Replays will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Alnylam Pharmaceuticals, Inc.

Christine Akinc

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

KEYWORDS: Nevada Massachusetts Florida United States North America

INDUSTRY KEYWORDS: Health Other Science Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

People with exocrine pancreatic insufficiency currently face highly disruptive pill burden – ANG003 expected to only require one tablet per meal

NEW YORK & NATICK, Mass.–(BUSINESS WIRE)–
Blackstone Life Sciences (“BXLS”) today announced a $250 million investment in Anagram Therapeutics (“Anagram”), a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis (“CF”), pancreatic cancer and related disorders. The investment will help fund the further development, approval and launch of Anagram’s ANG003, a novel orally delivered recombinant enzyme replacement therapy that has demonstrated positive clinical data in people with exocrine pancreatic insufficiency (“EPI”) due to CF. This community currently faces a highly disruptive pill burden, taking up to 40 pills daily. Additionally, ANG003 has the potential to be the first non-porcine extract product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507120898/en/

“We believe Anagram is well positioned to transform the treatment of pancreatic insufficiency, especially in patients of all ages who suffer from cystic fibrosis,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “This is an excellent case study of our ownership strategy where we bring scale capital, deep domain expertise, and hands-on engagement to help address large unmet medical needs.”

“We would like to thank the Blackstone Life Sciences team for their support and expertise as we accelerate the development of ANG003 and other orally delivered enzymes for people living with rare diseases. We believe the clinical data generated from the ANG003-22-101 study in patients with EPI due to CF is compelling and has the potential to be a transformational treatment for people living with EPI,” said Robert Gallotto, President and CEO, Anagram. “We are excited to be working with the entire Blackstone Life Sciences team and would also like to acknowledge and express our gratitude to the CF Foundation and its President and CEO Dr. Michael Boyle for their continued support from the initial stages to advance ANG003, a much-needed treatment option for people with CF and others living with EPI.”

“The large unmet need in EPI is clear as gastrointestinal symptoms and global supply issues for existing porcine derived products continue to be a real problem. Patients today also face an enormous, disruptive pill burden, taking up to 40 pills a day to treat their EPI. We expect ANG003 to only require one tablet per meal which we believe will positively impact compliance and quality of life,” said Kiran Reddy, MD, Senior Managing Director, Blackstone Life Sciences. “ANG003 represents a meaningful advancement for the many patients affected by this condition, offering the potential to significantly reduce treatment burden while improving clinical outcomes. We are excited to work with the CF patient and clinical community.”

BXLS’ support follows over $30 million in funding from the Cystic Fibrosis Foundation that enabled much of the clinical and development work to date for ANG003. ANG003 is a novel broad-spectrum orally delivered non-porcine enzyme replacement therapy being developed for people with CF and other conditions who also suffer from EPI. People with EPI do not produce enough pancreatic (digestive) enzymes to break down foods and absorb nutrients, which can lead to malnutrition, fatty acid abnormalities, profound gastrointestinal symptoms, a significant decrease in quality of life and reduced life expectancy. Gastrointestinal issues remain as one of the most burdensome challenges faced by people with CF. Anagram is initiating an international Phase 2 study with ANG003 after presenting positive data from an earlier clinical study in people with EPI due to CF.

About ANG003 and Exocrine Pancreatic Insufficiency

ANG003 is Anagram’s lead product for the treatment of exocrine pancreatic insufficiency (EPI) and malabsorption. ANG003 is a new class of broad-spectrum recombinant digestive enzyme replacement therapy, targeting some of the most challenging diseases in infants, children, and adults. ANG003 was engineered to be stable and immediately active in the gastrointestinal tract to maximize digestion and absorption. ANG003 contains lipase for fat malabsorption, protease for protein malabsorption, and amylase for carbohydrate malabsorption. EPI is a condition that is caused by reduced pancreatic enzymes, leading to impaired digestion, inadequate nutrient absorption, and associated with significantly diminished quality of life and life expectancy. People with EPI are currently treated with pancreatic enzyme replacement therapies (PERT) from pig pancreas glands that have a high treatment burden, requiring people to take up to 40 capsules per day. Pig-derived PERT require a significant amount of plastic coating to prevent it from being degraded in the stomach. PERT derived from pig pancreas glands continue to experience global product shortages. The current U.S. PERT market is approximately $2 billion annually.

About Blackstone Life Sciences

Blackstone Life Sciences (BXLS) is a leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $17 billion in assets under management.

About Anagram Therapeutics

Anagram Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of serious diseases caused by malabsorption syndromes and nutrient metabolism disorders, a group of conditions caused by enzyme deficiencies or genetic disorders that prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. The company is leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can have a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. ANG003, Anagram’s lead product for the treatment of malabsorption and exocrine pancreatic insufficiency, is a new class of broad-spectrum digestive enzyme replacement therapy in clinical trials in people with exocrine pancreatic insufficiency due to cystic fibrosis. Anagram is a privately held company headquartered in Natick, MA. To learn more, visit https://anagramtx.com/ or follow us on LinkedIn and X/Twitter.

Anagram Therapeutics® is a registered trademark of Anagram Therapeutics, Inc.

Blackstone

David Vitek

[email protected]

(212) 583-5291

Anagram Contact:

Kathryn Kilroy

[email protected]

(617) 466-3823

Anagram Media Contact:

Gina Cella

[email protected]

(781) 799-3137

KEYWORDS: New York Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Finance Oncology Health Asset Management Professional Services Clinical Trials

MEDIA:

Logo
Logo
Logo
Logo

Navitas to Participate at Upcoming Investor Conferences

TORRANCE, Calif., May 07, 2026 (GLOBE NEWSWIRE) — Navitas Semiconductor, (Nasdaq: NVTS), an industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) power semiconductors, today announced that Chris Allexandre, CEO, and Tonya Stevens, CFO, will host one-on-one meetings with investors and analysts registered to attend the following investor conferences:

  • CJS Securities 2

    nd

    Annual Spring 1×1 Conference
    Participation Date: May 13, 2026
    Venue: Virtual
  • J.P. Morgan Global Technology, Media & Communications Conference

    Participation Date: May 19, 2026
    Venue: Westin Seaport District Hotel, Boston

Portfolio managers and analysts can request a meeting with management by contacting their sales representative at the respective hosting firms.

About Navitas

Navitas Semiconductor (Nasdaq: NVTS) is a next-generation power semiconductor leader in gallium nitride (GaN) and IC integrated devices, and high-voltage silicon carbide (SiC) technology, driving innovation across AI data centers, performance computing, energy and grid infrastructure, and industrial electrification. With more than 30 years of combined expertise in wide bandgap technologies, GaNFast™ power ICs integrate GaN power, drive, control, sensing, and protection, delivering faster power delivery, higher system density, and greater efficiency. GeneSiC™  high-voltage SiC devices leverage patented trench-assisted planar technology to provide industry-leading voltage capability, efficiency, and reliability for medium-voltage grid and infrastructure applications. Navitas has over 300 patents issued or pending and is the world’s first semiconductor company to be CarbonNeutral®-certified.

Navitas Semiconductor, GaNFast, GaNSense, GeneSiC, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited and affiliates. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Investor Relations Contacts:

Shelton Group
Leanne Sievers | Brett Perry
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/868101a2-7cda-489f-8c4f-e2f9c2618358



VanEck Launches WARP ETF for Access to Rapidly Expanding Space Economy

VanEck Launches WARP ETF for Access to Rapidly Expanding Space Economy

WARP offers investors targeted exposure to the companies driving the commercialization of space, from satellite infrastructure to reusable rockets and AI-powered Earth observation.

NEW YORK–(BUSINESS WIRE)–VanEck today launched the VanEck Space ETF (Nasdaq: WARP), designed to provide investors with targeted exposure to leading companies in the rapidly developing space sector, as space transitions from being a government monopoly to a private market opportunity.

The global space economy is estimated to be over $600B and is expected to triple by 2035 as several structural tailwinds accelerate commercialization.1 Falling launch costs, fueled by reusable rocket technology, have fundamentally changed the economics of reaching orbit, while demand for more satellite infrastructure continues to expand, with roughly 2.2 billion people still lacking reliable broadband access.2 Governments are also treating space as a strategic domain, driving higher defense spending globally. Advances in artificial intelligence (AI) are also unlocking new capabilities in Earth observation, enabling real-time intelligence and new revenue streams for companies prioritizing space data and analytics.

“Space is becoming a distinct and investable theme, supported by powerful long-term growth drivers. The economics of space are changing rapidly, allowing for a growing universe of investable companies with meaningful commercial exposure,” said Nick Frasse, Product Manager with VanEck. “WARP offers focused exposure to companies primarily involved in launch systems, satellite infrastructure and space-enabled data.”

WARP seeks to track the MarketVector Space Index (MVWARP), which organizes the commercial space opportunity around the core building blocks of the ecosystem, including satellite communications, rockets and propulsion systems, Earth observation and data, and space exploration and related technologies. The index is designed with a pure-play approach, requiring companies to derive at least 50% of their revenues from space-related activities. It targets a focused portfolio using a modified float-adjusted market capitalization-weighted methodology, applies single-security caps and is reconstituted quarterly.

VanEck has an extensive track record of identifying and delivering investment solutions for structural shifts early. The firm is a leader in thematic investing, offering ETFs providing access to long-term growth trends shaping the global economy. The launch of WARP builds on VanEck’s lineup of innovation-focused strategies, including the VanEck Semiconductor ETF (SMH) and VanEck Fabless Semiconductor ETF (SMHX), for semiconductors exposure; the VanEck Robotics ETF (IBOT), focused on automation and AI; and the VanEck Pharmaceutical ETF (PPH) and VanEck Biotech ETF (BBH), which offer access to healthcare innovation.

“We’ve long designed our thematic ETFs to offer precise exposure to the long-term trends shaping the global economy,” said Ed Lopez, Head of Product at VanEck. “With WARP, we’re extending that approach, allowing investors to get concentrated and targeted exposure to companies leading the commercialization of space.”

Visit the WARP fund page for more information on the ETF and investing in space: vaneck.com/warp. The VanEck team also provides regular updates and research insights on its website.

About VanEck

VanEck has a history of looking beyond the financial markets to identify trends that are likely to create impactful investment opportunities. We were one of the first U.S. asset managers to offer investors access to international markets. This set the tone for the firm’s drive to identify asset classes and trends – including gold investing in 1968, emerging markets in 1993, and exchange traded funds in 2006 – that subsequently shaped the investment management industry.

Today, VanEck offers active and passive strategies with compelling exposures supported by well-designed investment processes. As of March 31, 2026, VanEck managed approximately $199.1 billion in assets, including mutual funds, ETFs and institutional accounts. The firm’s capabilities range from core investment opportunities to more specialized exposures to enhance portfolio diversification. Our actively managed strategies are fueled by in-depth, bottom-up research and security selection from portfolio managers with direct experience in the sectors and regions in which they invest. Investability, liquidity, diversity, and transparency are key to the experienced decision-making around market and index selection underlying VanEck’s passive strategies.

Since our founding in 1955, putting our clients’ interests first, in all market environments, has been at the heart of the firm’s mission.

Important Disclosures

This is not an offer to buy or sell, or a recommendation to buy or sell any of the securities, financial instruments or digital assets mentioned herein. The information presented does not involve the rendering of personalized investment, financial, legal, tax advice, or any call to action. Certain statements contained herein may constitute projections, forecasts and other forward-looking statements, which do not reflect actual results, are for illustrative purposes only, are valid as of the date of this communication, and are subject to change without notice. Actual future performance of any assets or industries mentioned are unknown. Information provided by third party sources are believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. VanEck does not guarantee the accuracy of third party data. The information herein represents the opinion of the author(s), but not necessarily those of VanEck or its other employees.

An investment in the VanEck Space ETF (WARP) may be subject to risks which include, among others, risks related to investing in space companies, equity securities, industrials sector, communication services sector, foreign securities, foreign currency, depositary receipts, small-cap, medium-cap and, large-cap companies, market, operational, index tracking, authorized participant concentration, new fund, no guarantee of active trading market, trading issues, passive management, fund shares trading, premium/discount, liquidity of fund shares, non-diversified, and index-related concentration risks, all of which may adversely affect the Fund. Large-capitalization companies may be subject to elevated risks.

MarketVector Space Index (MVWARP) is a rules-based, modified float-adjusted market capitalization weighted index designed to track the performance of Space Companies, defined as companies deriving at least 50% of revenues from space exploration, rockets and propulsion systems, satellite equipment and communications, or other satellite equipment including earth observation and GPS.

The principal risks of investing in VanEck ETFs include sector, market, economic, political, foreign currency, world event, index tracking, active management, social media analytics, derivatives, blockchain, commodities and non-diversification risks, as well as fluctuations in net asset value and the risks associated with investing in less developed capital markets. The Funds may loan their securities, which may subject them to additional credit and counterparty risk. ETFs that invest in high-yield securities are subject to risks associated with investing in high-yield securities; which include a greater risk of loss of income and principal than funds holding higher-rated securities; concentration risk; credit risk; hedging risk; interest rate risk; and short sale risk. ETFs that invest in companies with small capitalizations are subject to elevated risks, which include, among others, greater volatility, lower trading volume and less liquidity than larger companies. Please see the prospectus of each Fund for more complete information regarding each Fund’s specific risks.

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of a Fund carefully before investing. To obtain a prospectus and summary prospectus, which contain this and other information, call 800.826.2333 or visit vaneck.com. Please read the prospectus and summary prospectus carefully before investing.

_____________________

1 Source: McKinsey

2 Source: ITU Council

©️ Van Eck Securities Corporation, Distributor, a wholly owned subsidiary of Van Eck Associates Corporation

666 Third Avenue, New York, NY 10017

Phone: 800.826.2333

Email: [email protected]

Media Contact

Chris Sullivan

Craft & Capital

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Mobile/Wireless Networks Accounting Professional Services Hardware Technology Satellite Other Professional Services Insurance Finance Other Technology

MEDIA:

Logo
Logo

BUYOUT INVESTIGATION ALERT: Kaskela Law Firm Announces Investigation into Fairness of Global Business Travel Group Inc. Shareholder Buyout and Encourages Investors to Contact the Firm – GBTG

BUYOUT INVESTIGATION ALERT: Kaskela Law Firm Announces Investigation into Fairness of Global Business Travel Group Inc. Shareholder Buyout and Encourages Investors to Contact the Firm – GBTG

PHILADELPHIA–(BUSINESS WIRE)–
Investor protection firm Kaskela Law is investigating Global Business Travel Group, Inc. (NYSE: GBTG) (“Amex GBT”) on behalf of the company’s shareholders to determine whether the recently announced buyout of GBTG shareholders is fair and provides investors with sufficient monetary consideration for their shares.

Click here for additional information: https://kaskelalaw.com/case/global-business-travel-group/

On May 4, 2026, Amex GBT announced that it had agreed to be privatized for $9.50 per share in cash. Upon completion of the proposed transaction, Amex GBT’s public shareholders will be cashed out of their investment position, and the company’s shares will no longer be publicly traded.

Our investigation has discovered that the transaction appears to have significant conflicts of interest, thus making the sales process and proposed $9.50 per share price unfair to Amex GBT shareholders. Notably, at the time the buyout was announced, at least one stock analyst was maintaining a price target for Amex GBT’s shares of $12.00 per share – over 25% higher than the buyout price.

Amex GBT shareholders who feel that the buyout price is too low are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email at [email protected], for additional information about their legal rights and options. Investors may also request additional information about this matter by clicking on the following link (or by copying and pasting the link into your browser):

https://kaskelalaw.com/case/global-business-travel-group/

ABOUT KASKELA LAW:

Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent-fee basis. For additional information about the firm, including the firm’s recent monetary recoveries for investors in mergers & acquisition litigation, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 – 1740.

This communication may constitute attorney advertising in certain jurisdictions.

KASKELA LAW LLC

D. Seamus Kaskela, Esquire

Adrienne Bell, Esquire

18 Campus Boulevard, Suite 100

Newtown Square, PA 19073

(484) 229 – 0750

www.kaskelalaw.com

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Amphenol Announces Second Quarter 2026 Dividend

Amphenol Announces Second Quarter 2026 Dividend

WALLINGFORD, Conn.–(BUSINESS WIRE)–
Amphenol Corporation (NYSE: APH) announced today that its Board of Directors approved the second quarter 2026 dividend on its Common Stock in the amount of $0.25 per share at its meeting held on May 6, 2026. The Company will pay this first quarter 2026 dividend on July 15, 2026 to shareholders of record as of June 23, 2026.

About Amphenol

Amphenol Corporation is one of the world’s largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products and coaxial, high-speed, fiber optic and specialty cable. Amphenol designs, manufactures and assembles its products at facilities in approximately 40 countries around the world and sells its products through its own global sales force, independent representatives and a global network of electronics distributors. Amphenol has a diversified presence as a leader in high-growth areas of the interconnect market including: Automotive, Commercial Aerospace, Communications Networks, Defense, Industrial, Information Technology and Data Communications and Mobile Devices. For more information, visit www.amphenol.com.

Sherri Scribner

Vice President, Strategy and Investor Relations

203-265-8820

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Mobile/Wireless Networks Other Defense General Health Technology Defense Semiconductor Audio/Video Automotive Manufacturing Aerospace Manufacturing Health

MEDIA:

Logo
Logo

Enphase Energy Announces New Safe Harbor Agreement from U.S. TPO Provider

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) —  Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced a new safe harbor agreement with a U.S. solar and battery financing company that offers third-party ownership (TPO) agreements to homeowners and businesses, including leases and power purchase agreements (PPAs).

The new agreement was signed on April 28, 2026, and is expected to generate approximately $52 million in revenue. It covers Enphase® IQ9™ Microinverters for both residential and commercial solar projects, with products supplied from manufacturing facilities in the United States.

With this agreement, Enphase’s total physical work test (PWT) order backlog with TPO providers is now approximately $873.7 million. This total includes approximately $67.7 million signed in the fourth quarter of 2025, approximately $754 million signed earlier in 2026, and the approximately $52 million signed on April 28, 2026. Enphase expects revenue associated with this PWT backlog to be recognized between 2027 to 2030, subject to customer project timing, demand, and other factors.

This PWT backlog covers IQ9 Microinverters only. Cables, accessories, and IQ® Batteries represent additional revenue opportunities that may be attached to these microinverter systems over the same 2027 to 2030 period.

Safe harboring can help future projects preserve eligibility for the base investment tax credit (ITC) and the domestic content bonus credit. By safe harboring equipment now, solar companies can help reduce uncertainty around future project economics and support long-term deployment planning.

“This additional safe harbor agreement reflects the continued momentum we are seeing with TPO providers as they plan for future residential and commercial solar projects,” said Ken Fong, senior vice president of sales at Enphase Energy. “Our IQ9 Microinverters, supplied from U.S. manufacturing facilities, give our partners a high-quality solution as they prepare for deployments under evolving tax credit rules.”

Project developers should consult their own legal and tax advisors to confirm eligibility for available tax credits. To learn more about Enphase products and services, please visit the website.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 87.8 million microinverters, with more than 5.2 million Enphase-based systems deployed in over 165 countries. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the ability of financiers and installers to expand deployments of IQ9 Microinverters; the anticipated revenue from safe harbor agreements; the timing of revenue recognition associated with the safe harbor backlog; the ability of Enphase to generate new business with additional financing providers; and meeting eligibility requirements for the ITC and the domestic content tax bonus credit. These forward-looking statements are based on Enphase Energy’s current expectations and assumptions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, market demand; competitive dynamics; supply chain availability and costs; and other factors discussed in Enphase Energy’s filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy’s most recently filed Annual Report on Form 10‑K and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law.

Contact:

Enphase Energy
[email protected]



Uber Eats and Ulta Beauty Team Up to Deliver Beauty Essentials Nationwide, Expanding On-Demand Access to Both Prestige and Mass Favorites

Uber Eats and Ulta Beauty Team Up to Deliver Beauty Essentials Nationwide, Expanding On-Demand Access to Both Prestige and Mass Favorites

Just in time for Mother’s Day, more than 1,500 Ulta Beauty stores join Uber Eats, expanding on-demand access to must-have beauty, wellness, and self-care essentials

SAN FRANCISCO–(BUSINESS WIRE)–
Uber Technologies, Inc. (NYSE: UBER) and Ulta Beauty (NASDAQ: ULTA), the largest specialty beauty retailer in the U.S., today announced the addition of more than 1,500 Ulta Beauty stores to the Uber Eats marketplace. Just in time for Mother’s Day, customers across the U.S. can now shop an expansive assortment of beauty and wellness products—including makeup, skincare, haircare, fragrance, tools & devices and much more—for on-demand or scheduled delivery, giving customers more ways to find the perfect gift or restock everyday favorites.

With the addition of Ulta Beauty, Uber Eats continues to grow its beauty and retail selection, offering customers access to a wide range of products across categories and price points. From accessible essentials to coveted prestige brands, consumers can now browse thousands of products from more than 600 brands across Ulta Beauty’s assortment, all within the Uber Eats app for convenient, same-day delivery.

As always, Uber One members can also enjoy $0 Delivery Fee on eligible orders and other exclusive savings.†

“At Ulta Beauty, we’re focused on creating seamless, flexible ways for our guests to discover and shop the brands they love – whenever and wherever they need them,” said Jodi Williams, Vice President of eCommerce at Ulta Beauty. “Partnering with Uber Eats allows us to extend our omnichannel experience, bringing our differentiated assortment of beauty and wellness products directly to our guests’ doors with speed and convenience – whether they’re planning ahead or need something in the moment.”

The partnership reflects Uber Eats’ continued momentum in expanding beyond food delivery into everyday retail categories, including beauty, electronics, home improvement, and more. By adding Ulta Beauty’s nationwide footprint, Uber Eats is further strengthening its marketplace with greater selection and accessibility for customers across the country.

“Consumers today are looking for both variety and flexibility when it comes to shopping for beauty products,” said Hashim Amin, Head of Grocery and Retail for Uber in North America. “Our partnership with Ulta Beauty makes it easier for customers to discover and shop a wide range of beauty products, all delivered directly to their door—whether they need to refill their skincare essentials, shop for their mom’s favorite perfume for a last-minute gift, or any of the moments in between.”

How it Works

Getting your favorite beauty products delivered from Ulta Beauty through Uber Eats is simple:

  1. Open the Uber Eats app and tap into the “Retail” or “Beauty” category.

  2. Select your nearest Ulta Beauty location and browse a wide assortment of makeup, skincare, and more.

  3. Add items to your cart, choose your delivery time and place your order.

  4. Track your delivery in real time.

About Uber

Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 75 billion trips later, we’re building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

About Ulta Beauty

Ulta Beauty (NASDAQ: ULTA) is the largest specialty beauty retailer in the U.S. and a leading destination for cosmetics, fragrance, skincare, haircare, wellness and salon services. Since opening its first store in 1990, Ulta Beauty has grown to approximately 1,500 stores across the U.S. and redefined beauty retail by bringing together All Things Beauty. All in One Place®. With an expansive product assortment, professional salon services and its beloved Ulta Beauty Rewards loyalty program, the company delivers seamless, personalized experiences across stores, Ulta.com and the Ulta Beauty App – where the possibilities are truly beautiful. Ulta Beauty is also expanding its presence internationally through a joint venture in Mexico, a franchise in the Middle East, and its subsidiary, Space NK, a luxury beauty retailer operating in the U.K. and Ireland. For more information, visit www.ulta.com.

† Taxes and fees may still apply. See app for details.

Press Contacts

Uber: [email protected]

Ulta Beauty: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Apps/Applications Technology Women Electronic Commerce Specialty Delivery Services Consumer Cosmetics Retail Online Retail

MEDIA:

Logo
Logo

General Fusion to Present at Major Tech Industry and Key Investor Events in May

VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — General Fusion Inc. (“General Fusion” or the “Company”), a leader in the global race to commercialize fusion energy, today announced its participation in and presentations at several prominent conferences throughout May, including Web Summit, one of the world’s premier technology conferences with more than 20,000 attendees expected. General Fusion is on the path to becoming the first publicly traded pure-play fusion energy company. The Company previously announced its plans to go public through a business combination (the transactions contemplated by the business combination, collectively, the “Proposed Business Combination”) with Spring Valley Acquisition Corp. III (NASDAQ: SVAC) (“SVAC”). The transaction is targeted to close in mid-2026. Once completed, the combined company will operate as General Fusion and is expected to be listed on the Nasdaq under ticker “GFUZ.”

Conference Details:

  • Greg Twinney, CEO, is scheduled to speak in two sessions at Web Summit Vancouver, taking place at the Vancouver Convention Centre, May 11–14:
    • New Energy Summit Keynote — May 13 at 11:50 a.m. PT (Stage 3)
    • Startup University Fireside Chat on bringing fusion to the public markets — May 14 at 12:10 p.m. PT (Stage 4)
  • Megan Wilson, Chief Strategy Officer, is expected to deliver a keynote presentation at Canaccord Genuity’s Nuclear Nexus conference on May 13 in Cambridge, MA.
  • Greg Twinney, CEO, and Rob Crystal, Senior Vice President, Finance, also plan to attend the B. Riley Securities 26th Annual Institutional Investor Conference, taking place May 20–21 in Marina del Rey, CA.

If you are interested in arranging meetings with General Fusion during any of these events, please contact [email protected].

Quick Facts: 

  • General Fusion’s Magnetized Target Fusion (“MTF”) is designed to solve significant barriers to commercializing fusion energy at a time when electricity demand is surging, and nations around the world are racing to commercialize fusion power.
  • As a technology, MTF aims to achieve fusion in a practical way, avoiding superconducting magnets and high-powered lasers, while enabling the use of existing materials for durable machines that would produce cost-effective energy.
  • In early 2025, General Fusion announced that it had designed, built, and begun operating its world-first Lawson Machine 26 (“LM26”) fusion demonstration machine in under two years. LM26 is the first MTF demonstration machine to be built at a commercially relevant scale. It mechanically compresses plasma with a lithium liner at 50% commercial-scale diameter.
  • LM26 aims to achieve key fusion technical milestones: plasma heating to 1 keV (10 million degrees Celsius), then 10 keV (100 million degrees Celsius), and ultimately the Lawson criterion, the combination of fusion parameters that can produce net fusion energy in the plasma.

About General Fusion

General Fusion is pursuing a fast and practical approach to commercial fusion energy and is headquartered in Vancouver, Canada. The Company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com. General Fusion announced in January 2026 that it plans to go public through the Proposed Business Combination with Spring Valley Acquisition Corp. III (NASDAQ: SVAC).

About Spring Valley Acquisition Corp. III

Spring Valley Acquisition Corp. III is a part of a family of investment vehicles formed for the purpose of acquiring or merging with a business focused on the Power infrastructure and Decarbonization sectors. Over the past 5 years, Spring Valley has raised $920 million in four IPOs. Spring Valley I successfully completed its business combination with NuScale Power, a leading U.S. small modular reactor (“SMR”) technology company, and Spring Valley II successfully completed its business combination with Eagle Nuclear Energy Corp., a next-generation nuclear energy company with rights to the largest open pit-constrained measured and indicated uranium deposit in the United States. SVAC maintains a corporate website at https://sv-ac.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements included in this document are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “strategy,” “future,” “opportunity,” “may,” “target,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “preliminary,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, without limitation, SVAC’s, General Fusion’s, or their respective management teams’ expectations concerning the Proposed Business Combination and expected benefits or timing thereof; the outlook for General Fusion’s business, including its ability to commercialize MTF or any other fusion technology on its expected timeline or at all; statements regarding the current and expected results of General Fusion’s LM26 program; the ability to execute General Fusion’s strategies, including on any expected timeline or anticipated cost basis; projected and estimated financial performance; anticipated industry trends; future capital expenditures; government regulation of fusion energy; and environmental risks; as well as any information concerning possible or assumed future results of operations of General Fusion. The forward-looking statements are based on the current expectations of the respective management teams of SVAC and General Fusion, as applicable, and are inherently subject to uncertainties and changes in circumstance and their potential effects. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, (i) the risk that the Proposed Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of SVAC’s securities; (ii) the failure to satisfy the conditions to the consummation of the Proposed Business Combination, including the adoption of the business combination agreement, dated January 21, 2026, among General Fusion, SVAC, and the other party thereto (the “Business Combination Agreement”) by the shareholders of SVAC and the receipt of regulatory approvals; (iii) market risks; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement; (v) the effect of the announcement or pendency of the Proposed Business Combination on General Fusion’s business relationships, performance, and business generally; (vi) risks that the Proposed Business Combination disrupts current plans of General Fusion and potential difficulties in its employee retention as a result of the Proposed Business Combination; (vii) the outcome of any legal proceedings that may be instituted against General Fusion or SVAC related to the Business Combination Agreement or the Proposed Business Combination; (viii) failure to realize the anticipated benefits of the Proposed Business Combination; (ix) the inability to maintain the listing of SVAC’s securities or to meet listing requirements and maintain the listing of the combined company’s securities on Nasdaq; (x) the risk that the Proposed Business Combination may not be completed by SVAC’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by SVAC; (xi) the risk that the price of the combined company’s securities may be volatile due to a variety of factors, including changes in laws, regulations, technologies, natural disasters, national security tensions, and macro-economic and social environments affecting its business; (xii) laws and regulations governing General Fusion’s research and development activities, and changes in such laws and regulations; (xiii) any failure to commercialize MTF on the expected timeline or at all, including any failure to achieve the objectives of the LM26 program; (xiv) environmental regulations and legislation; (xv) the effects of climate change, extreme weather events, water scarcity, and seismic events, and the effectiveness of strategies to deal with these issues; (xvi) fluctuations in currency markets; (xvii) General Fusion’s ability to complete and successfully integrate any future acquisitions; (xviii) increased competition in the fusion industry; (xix) limited supply of materials and supply chain disruptions; and (xx) the risk that the proposed private placement of convertible preferred shares and warrants by General Fusion (the “PIPE Financing”) may not be completed, or that other capital needed by the combined company may not be raised on favorable terms, or at all, including as a result of the restrictions agreed to in connection with the PIPE Financing. The foregoing list is not exhaustive, and there may be additional risks that neither SVAC nor General Fusion presently know or that SVAC and General Fusion currently believe are immaterial. You should carefully consider the foregoing factors, any other factors discussed in this document and the other risks and uncertainties described in the “Risk Factors” section of SVAC’s final prospectus for its initial public offering, which was filed with the SEC on September 4, 2025 (the “Final Prospectus”); the risks described in the joint registration statement on Form F-4 filed by General Fusion and SVAC (the “Registration Statement”), which includes a preliminary proxy statement/prospectus, or to be described in any amendment or supplement thereto; and those discussed and identified in filings made with the SEC by SVAC from time to time. General Fusion and SVAC caution you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth in this document speak only as of the date of this document. Neither General Fusion nor SVAC undertakes any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that General Fusion or SVAC will make additional updates with respect to that statement, related matters, or any other forward-looking statements. Any corrections or revisions and other important assumptions and factors that could cause actual results to differ materially from forward-looking statements, including discussions of significant risk factors, may appear, up to the consummation of the Proposed Business Combination, in SVAC’s public filings with the SEC, which are or will be (as applicable) accessible at www.sec.gov, and which you are advised to review carefully.

Important Information for Investors and Shareholders

In connection with the Proposed Business Combination, General Fusion and SVAC filed with the SEC the Registration Statement, which includes a preliminary prospectus with respect to SVAC’s securities to be issued in connection with the Proposed Business Combination and a preliminary proxy statement in connection with SVAC’s solicitation of proxies for the vote by SVAC’s shareholders with respect to the Proposed Business Combination and other matters described in the Registration Statement (the “Proxy Statement”). After the SEC declares the Registration Statement effective, SVAC plans to file the definitive Proxy Statement with the SEC and to mail copies to SVAC’s shareholders as of a record date to be established for voting on the Proposed Business Combination. This document does not contain all the information that should be considered concerning the Proposed Business Combination and is not a substitute for the Registration Statement, Proxy Statement or for any other document that SVAC has filed or may file with the SEC. Before making any investment or voting decision, investors and security holders of SVAC and General Fusion are urged to read the Registration Statement and the Proxy Statement, and any amendments or supplements thereto, as well as all other relevant materials filed or that will be filed with the SEC in connection with the Proposed Business Combination as they become available because they will contain important information about General Fusion, SVAC and the Proposed Business Combination. Investors and security holders are able to obtain free copies of the Registration Statement, the Proxy Statement and all other relevant documents filed or that will be filed with the SEC by SVAC through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by SVAC may be obtained free of charge from SVAC’s website at https://sv-ac.com or by directing a request to Spring Valley Acquisition Corp. III, Attn: Corporate Secretary, 2100 McKinney Avenue, Suite 1675, Dallas, Texas 75201. The information contained on, or that may be accessed through, the websites referenced in this document is not incorporated by reference into, and is not a part of, this document. 

Participants in the Solicitation

General Fusion, SVAC and their respective directors, executive officers and other members of management and employees may, under the rules of the SEC, be deemed to be participants in the solicitations of proxies from SVAC’s shareholders in connection with the Proposed Business Combination. For more information about the names, affiliations and interests of SVAC’s directors and executive officers, please refer to the Final Prospectus and the Registration Statement, Proxy Statement and other relevant materials filed or to be filed with the SEC in connection with the Proposed Business Combination when they become available. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, which may, in some cases, be different than those of SVAC’s shareholders generally, will be included in the Registration Statement and the Proxy Statement, when they become available. Shareholders, potential investors and other interested persons should read the Registration Statement and the Proxy Statement carefully, when they become available, before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. 

No Offer or Solicitation

This document shall not constitute a “solicitation” as defined in Section 14 of the Securities Exchange Act of 1934, as amended. This document shall not constitute an offer to sell or exchange, the solicitation of an offer to buy or a recommendation to purchase, any securities, or a solicitation of any vote, consent or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. No offering of securities in the Proposed Business Combination shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. 

Investor Relations Contact:

You can contact General Fusion’s Investor Relations team by email at: [email protected].

If you are based in North America, you may also leave a toll-free voicemail at +1 (833) 717-1519. Callers outside North America can reach us at +1 (236) 253-6968. 

Media Relations Contact:


[email protected]
 
1-866-904-0995